# A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

> **NCT06138132** · PHASE1 · RECRUITING · sponsor: **Stanford University** · enrollment: 12 (estimated)

## Conditions studied

- Multiple Sclerosis
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive

## Interventions

- **BIOLOGICAL:** KYV-101 anti-CD19 CAR-T cell therapy
- **DRUG:** Standard lymphodepletion regimen

## Key facts

- **NCT ID:** NCT06138132
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-10
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06138132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06138132, "A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06138132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*